Skip to main content

Generic Namenda XR Availability

Last updated on Jan 11, 2023.

See also: Generic Namenda

Namenda XR is a brand name of memantine, approved by the FDA in the following formulation(s):

NAMENDA XR (memantine hydrochloride - capsule, extended release;oral)

Has a generic version of Namenda XR been approved?

A generic version of Namenda XR has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Namenda XR and have been approved by the FDA:

memantine hydrochloride capsule, extended release;oral

  • Manufacturer: AMNEAL PHARMS
    Approval date: October 12, 2016
    Strength(s): 7MG [AB], 14MG [AB], 21MG [AB], 28MG [AB]
  • Manufacturer: ANI PHARMS
    Approval date: February 28, 2020
    Strength(s): 28MG [AB]
  • Manufacturer: APOTEX
    Approval date: November 22, 2016
    Strength(s): 7MG [AB], 14MG [AB], 21MG [AB], 28MG [AB]
  • Manufacturer: AUROBINDO PHARMA LTD
    Approval date: August 9, 2021
    Strength(s): 7MG [AB], 14MG [AB], 21MG [AB], 28MG [AB]
  • Manufacturer: LUPIN LTD
    Approval date: September 28, 2016
    Strength(s): 7MG [AB], 14MG [AB], 21MG [AB], 28MG [AB]
  • Manufacturer: XIAMEN LP PHARM CO
    Approval date: October 11, 2022
    Strength(s): 7MG [AB], 14MG [AB], 28MG [AB]
  • Manufacturer: YICHANG HUMANWELL
    Approval date: April 2, 2021
    Strength(s): 7MG [AB], 14MG [AB], 21MG [AB], 28MG [AB]
  • Manufacturer: ZYDUS PHARMS
    Approval date: August 3, 2017
    Strength(s): 7MG [AB], 14MG [AB], 21MG [AB], 28MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Namenda XR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Modified release formulations of memantine oral dosage forms
    Patent 8,039,009
    Issued: October 18, 2011
    Inventor(s): Rastogi; Suneel K. & Rao; Niranjan & Periclou; Antonia & Abramowitz; Wattanaporn & Dedhiya; Mahendra G. & Mahashabde; Shashank
    Assignee(s): Forest Laboratories Holdings Limited

    The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.

    Patent expiration dates:

    • March 24, 2029
    • September 24, 2029
      Pediatric exclusivity


Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.